Biodesix, Inc. (BDSX)
| Previous close | 1.2800 |
| Open | 1.2800 |
| Bid | 1.2200 x 100 |
| Ask | 1.3100 x 100 |
| Day's range | 1.2550 - 1.2800 |
| 52-week range | 1.0300 - 2.2100 |
| Volume | |
| Avg. volume | 139,619 |
| Market cap | 144.504M |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024
LOUISVILLE, Colo., April 24, 2024--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the first quarter ended March 31, 2024 after the close of trading on Wednesday, May 8. Biodesix’s management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
- Business Wire
Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting
LOUISVILLE, Colo., April 09, 2024--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California. These presentations highlight advancements in liquid biopsy technologies that detect cell free DNA (cfDNA) and the clinical value of rapid turnaround time to detect actionable tumor mutations in a real-world clinical set
- Business Wire
Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement
LOUISVILLE, Colo., April 05, 2024--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced the pricing of its underwritten offering of 17,391,832 shares of its common stock at a price to the public of $1.15 per share. In addition, Biodesix has entered into securities purchase agreements for a concurrent private placement of 760,857 shares of its Series A Non-Voting Convertible Preferred Stock at a price of $46.00 per share. Subject to B
